Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 56%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc. is experiencing significant revenue growth driven by its Signatera molecular residual disease test, which reported a 54% year-over-year increase in volumes. The company anticipates expanding its reimbursement coverage for additional cancer types, potentially leading to increased average selling prices (ASP), improved gross margins, and enhanced operating cash flow. Furthermore, Natera's impressive performance in the most recent quarter includes an approximately $80 million revenue beat, alongside a raised revenue guidance for 2025, reflecting continued positive momentum.

Bears say

Natera Inc. faces a negative outlook due to anticipated margin erosion stemming from reductions in in-network pricing as it expands its total addressable market (TAM) to include more average-risk patients. Regulatory setbacks, reimbursement issues, or delays in product launches could further amplify financial vulnerabilities, potentially leading to significant stock depreciation. Additionally, challenges related to compelling data and adoption in emerging markets may hinder the company's growth prospects, raising concerns about its ability to achieve projected financial targets.

Natera (NTRA) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 56% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 16 analysts, Natera (NTRA) has a Buy consensus rating as of Jan 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $246.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $246.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.